B ZAHOROWSKA1, S D ROGER2 1Liverpool Hospital, Liverpool, New South Wales, 2Gosford Hospital, Gosford, New South Wales Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been available in Australia for 4 years as sole therapy or in combination therapy for type...
- 4 August 2017
RG LANGHAM1,2, S MARTINI3, F EICHINGER3, V NAIR3, Y ZHANG1, A COX1, M KRETZLER3, D J KELLY1 1St. Vincent’s Hospital University of Melbourne Department of Medicine, Fitzroy, VIC; 2Monash University School of Rural Health, Clayton, VIC 3University of Michigan, Ann Arbour, MI,...
- 4 August 2017
MR SUTHERLAND1,2, KL BRAIN1, KJ BOTTING1, SN AUSTIN-WILLIAMS1, EJ CAMM1, DA GIUSSANI1 1University of Cambridge, Cambridge, United Kingdom; 2Monash University, Clayton, VIC Aim: To determine the impact of chronic fetal hypoxia, with and without maternal antioxidant treatment, on renal morphology in...
- 4 August 2017
J C JHA1,2, M T COUGHLAN1,2, D A. POWER3, A SKENE4, E I. EKINCI5, M E. COOPER1,2, C R. KENNEDY6, K JANDELEIT-DAHM1,2. 1Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; 2Baker IDI Heart and Diabetes Institute, Melbourne, Australia;...
- 4 August 2017
TD HEWITSON1,2, SG HOLT1,2, SJ TAN1, B WIGG1, CS SAMUEL3, ER SMITH1,2 1Department of Nephrology, The Royal Melbourne Hospital, Parkville, Melbourne, VIC; 2Department of Medicine-RMH, University of Melbourne, Parkville, Melbourne, VIC; 3Department of Pharmacology, Monash University, Clayton, Melbourne, VIC, Australia. Aim: To...
- 4 August 2017
M LEE1,2, PF MOUNT1, M KATERELOS1, K GLEICH1, DA POWER1,2. 1Kidney Laboratory, Department of Nephrology, Austin Health, Heidelberg, VIC; 2Department of Medicine, The University of Melbourne, Heidelberg, VIC Aim: To determine whether reduced fatty acid oxidation contributes to renal fibrosis. Background:...
- 4 August 2017